FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BIENAIME JEAN JACQUES 		2. Issuer Name and Ticker or Trading Symbol

BIOMARIN PHARMACEUTICAL INC [ BMRN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST. 		3. Date of Earliest Transaction (MM/DD/YYYY)

9/15/2016
(Street)

SAN RAFAEL, CA 94901
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   9/15/2016   (1) 9/15/2016   M    42577   A $17.33   421161   D    
Common Stock   9/15/2016   (1) 9/15/2016   S    42577   D $94.8484   (2) 378584   D    
Common Stock   9/16/2016   (1) 9/16/2016   M    53125   A $38.59   431709   D    
Common Stock   9/16/2016   (1) 9/16/2016   S    53125   D $95.2478   (3) 378584   D    
Common Stock   9/16/2016   (4) 9/16/2016   M    41666   A $17.54   420250   D    
Common Stock   9/16/2016   (4) 9/16/2016   S    41666   D $95.967   (5) 378584   D    
Common Stock                  25758   I   Shares held by Bienaime Family Trust  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy Common Stock)   $17.33   9/15/2016   (1) 9/15/2016   M         42577    12/7/2007   6/6/2017   Common Stock   42577   $0   117423   (6) D    
Stock Option (right to buy Common Stock)   $38.59   9/16/2016   (1) 9/16/2016   M         53125    11/22/2008   5/21/2018   Common Stock   53125   $0   371875   (6) D    
Stock Option (right to buy Common Stock)   $17.54   9/16/2016   (4) 9/16/2016   M         41666    5/20/2007   11/19/2016   Common Stock   41666   $0   83336   (6) D    

Explanation of Responses:
( 1)  Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime.
( 2)  The price in column 4 is the weighted average price. The price actually received ranged from $94.02 to $96.72. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
( 3)  The price in column 4 is the weighted average price. The price actually received ranged from $94.02 to $97.20. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
( 4)  Trade made pursuant to a 10b5-1 plan executed on August 17, 2015. Mr. Bienaime's former spouse will receive approximately 17% of the net proceeds from the sale of these shares pursuant to a marital separation agreement between Mr. Bienaime and his former spouse.
( 5)  The price in column 4 is the weighted average price. The price actually received ranged from $94.365 to $97.21. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
( 6)  Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL, CA 94901 		X
Chief Executive Officer

Signatures
/s/ Laura Randall Woodhead, Attorney-in-Fact 9/19/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioMarin Pharmaceutical Charts.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioMarin Pharmaceutical Charts.